Hikma Pharmaceuticals PLC (HIK.L)
LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
As of 10:43AM BST. Market open.
| Previous close | 1,956.00 |
| Open | 1,963.00 |
| Bid | 1,971.00 x 0 |
| Ask | 1,974.00 x 0 |
| Day's range | 1,959.00 - 1,994.00 |
| 52-week range | 1,711.00 - 2,222.00 |
| Volume | |
| Avg. volume | 619,927 |
| Market cap | 4.371B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 28.97 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.57 (2.93%) |
| Ex-dividend date | 21 Mar 2024 |
| 1y target est | N/A |
- Simply Wall St.
With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns
Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...
- Simply Wall St.
Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
- Reuters
Merck's Bridion faces generic threat from drugmaker Hikma
Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing on Monday. Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand-name drug. Merck said in the filing that it is currently considering its options.
© 2024 Yahoo. All rights reserved.